Start-Up Previews (11/04)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Biotechs Battle Bacteria, features profiles of AureoGen Biosciences, Biovertis, Inimex Pharmaceuticals and Prolysis. Plus these Start-Ups across Health Care: Afmedica, Intercept Pharmaceuticals and MAP Pharmaceuticals.
You may also be interested in...
CEO Nello Mainolfi talked to Scrip about Kymera’s pipeline expansion, which will prioritize oral targeted protein degraders in immunology, including two new assets moving into the clinic.
Despite Mark’s relatively upbeat attitude, FDA experts warn that even absent a government shutdowns or minimally impactful ones, the current cycle of continuing resolutions and the lingering threat of budget sequestration is harmful to the agency’s operation.
However, David Kaslow, director of the FDA’s vaccines office, says only a ‘may’ recommendation is supported and that giving an extra dose after June ‘may not be optimal’ if vaccines are reformulated for the fall.